What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies? | Zendy

TzuFei Wang | Zendy; Wendy Lim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?

Author(s) -

TzuFei Wang,

Wendy Lim

Publication year - 2016

Publication title -

hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.321

H-Index - 91

eISSN - 1520-4391

pISSN - 1520-4383

DOI - 10.1182/asheducation-2016.1.714

Subject(s) - hydroxychloroquine , medicine , antibody , antiphospholipid syndrome , thrombosis , immunology , disease , covid-19 , infectious disease (medical specialty)

A 35-year-old man presents with an acute unprovoked deep vein thrombosis of the left lower extremity. He is treated with anticoagulation and elects to discontinue treatment after 6 months. He subsequently develops polyarthralgias, fatigue, and a malar rash, and a diagnosis of systemic lupus erythematosus is made based on laboratory and clinical findings. Additional laboratory testing reveals persistent triple positive antiphospholipid antibodies, including lupus anticoagulant, high titer anticardiolipin antibodies, and anti–β2-glycoprotein I antibodies. The patient is reinitiated on anticoagulation, and the patient’s rheumatologist inquires if the addition of hydroxychloroquine could help to prevent recurrent thrombosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research